Clinical trial
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating…
NCT00112879 · The Cleveland Clinic, Other · Withdrawn
Key facts
| NCT number | NCT00112879 |
|---|---|
| Title | Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma |
| Official title | Phase II Study of Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Patients With Previously Untreated High-Risk or Relapsed or Refractory Multiple Myeloma |
| Lead sponsor | The Cleveland Clinic, Other |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm |
| Intervention type | Drug, Procedure |
| Interventions | arsenic trioxide, ascorbic acid, dexamethasone, thalidomide, anti-cytokine therapy, antiangiogenesis therapy, biological therapy, chemotherapy, drug resistance inhibition, growth factor antagonist therapy and 1 more |
| Enrollment | 0 |
| First posted | Jun 3, 2005 |
| Last update posted | Jul 10, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: